AF
RAPT

Amalgamated Financial’s RAPT Therapeutics RAPT Stock Holding History

Amalgamated Financial’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$76K Buy
+434
New +$82K ﹤0.01% 2253

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Amalgamated Financial's RAPT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in RAPT Therapeutics (RAPT) in Q1 2022: 434 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2253 among its holdings.

85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

  • Amalgamated Financial held 434 shares of RAPT Therapeutics worth $76K as of Q1 2022.
  • RAPT Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • RAPT Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2253 holding.
  • 85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.